A novel disulfide-stabilized single-chain variable antibody fragment against rabies virus G protein with enhanced in vivo neutralizing potency

Duan, Ye; Gu, Tiejun; Jiang, Chunlai; Yuan, Ruosen; Zhang, Hua-fei; Hou, Hongjia; Yu, Xianghui; Chen, Yan; Zhang, Yong; Wu, Yongge; Kong, Wei

doi:10.1016/j.molimm.2012.03.015

Cited by 22 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antibody variable domains can be engineered into small fragments ( Table 2), including scFvs and F[ab] molecules [76][77][78] which do not require production in costly eukaryotic expression systems. Several of these small antibody fragments have been investigated regarding their antiviral activities [79,80], including camelid VHH domains.…”

Section: Antibody Engineeringmentioning

confidence: 99%

Monoclonal antibodies for prophylactic and therapeutic use against viral infections

et al. 2013

View full text Add to dashboard Cite

Section: Antibody Engineeringmentioning

confidence: 99%

Monoclonal antibodies for prophylactic and therapeutic use against viral infections

et al. 2013

View full text Add to dashboard Cite

“…reports that a bivalent disulfide‐stabilized Fv could bind to erbB2 with improved antigen‐binding activity compared to Fv. Duan et al . constructed a disulfide‐stabilized scFv against RV (ds‐FV57); the stability of ds‐FV57 was notably improved, and its neutralizing potency against RV infection was enhanced in vitro .…”

Section: Discussionmentioning

confidence: 99%

Construction of a disulfide‐stabilized diabody against fibroblast growth factor‐2 and the inhibition activity in targeting breast cancer

et al. 2016

View full text Add to dashboard Cite

Fibroblast growth factor‐2 (FGF‐2) is one of the most important angiogenic factors to promote tumor growth, progression and metastasis. Neutralizing antibodies against FGF‐2 may suppress the growth of tumor cells by blocking the FGF‐2 signaling pathway. In this study, a disulfide‐stabilized diabody (ds‐Diabody) that specifically targets FGF‐2 was designed. Compared to its parent antibody, the introduction of disulphide bonds in the diabody could significantly increase the stability of ds‐Diabody and maintain its antigen binding activity. The ds‐Diabody against FGF‐2 could effectively inhibit the tube formation and migration of vascular endothelial cells and block the proliferation and invasion of human breast cancer cells. In the mouse model of breast cancer xenograft tumors, the ds‐Diabody against FGF‐2 could significantly inhibit the growth of tumor cells. Moreover, the densities of microvessels stained with CD31 and lymphatic vessels stained with LYVE1 in tumors showed a significant decrease following treatment with the ds‐Diabody against FGF‐2. Our data indicated that the ds‐Diabody against FGF‐2 could inhibit tumor angiogenesis, lymphangiogenesis and tumor growth.

show abstract

“…Owing to their several advantages, single chain antibodies could serve as useful tools for antibody-based therapies. Better penetration to target tissues because of the small size [16,40] has made scFvs more effective than antibodies in therapeutic applications especially when viral antigens are the targets [41,42].…”

Section: Discussionmentioning

confidence: 99%

Neutralizing human recombinant antibodies against herpes simplex virus type 1 glycoproteins B from a phage-displayed scFv antibody library

et al. 2017

View full text Add to dashboard Cite

The HSV-1 envelope glycoprotein B (gB) plays a critical role in virus entry into host cells. Neutralizing antibodies can therefore potentially prevent virus entry into target cells and cell-to-cell spread of infection. Our present study focused on the selection of neutralizing single-chain Fv (scFv) antibodies of a phage-displayed nonimmune human scFv antibody library against gB of HSV-1. To enrich specific scFvs, two phage antibodies were isolated against amino acid residues 31-43 derived from the N-terminal part of gB using panning technique. Two scFvs, scFv-gB and scFv-gB, with frequencies of 45% and 20% were obtained from scFv clones after performing PCR and MvaI fingerprinting. In phage ELISA analysis, both gB and gB scFvs demonstrated high reactivity with the gB peptide. In the neutralization assay, scFv-gB and scFv-gB represented neutralizing effects of 55% and 59%, respectively. Upon further enhancement of the neutralizing effects of these antibodies, they can be considered as new potential alternatives in the treatment and prophylaxis of HSV-1 infections.

show abstract

A novel disulfide-stabilized single-chain variable antibody fragment against rabies virus G protein with enhanced in vivo neutralizing potency

Cited by 22 publications

References 37 publications

Monoclonal antibodies for prophylactic and therapeutic use against viral infections

Monoclonal antibodies for prophylactic and therapeutic use against viral infections

Construction of a disulfide‐stabilized diabody against fibroblast growth factor‐2 and the inhibition activity in targeting breast cancer

Neutralizing human recombinant antibodies against herpes simplex virus type 1 glycoproteins B from a phage-displayed scFv antibody library

Contact Info

Product

Resources

About